MX2023000943A - Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos. - Google Patents
Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos.Info
- Publication number
- MX2023000943A MX2023000943A MX2023000943A MX2023000943A MX2023000943A MX 2023000943 A MX2023000943 A MX 2023000943A MX 2023000943 A MX2023000943 A MX 2023000943A MX 2023000943 A MX2023000943 A MX 2023000943A MX 2023000943 A MX2023000943 A MX 2023000943A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydroimidazolone
- tetrahydropyrazolo
- pyridinyl
- pyrazinyl
- compounds
- Prior art date
Links
- DLXWQDKMPJRDRU-UHFFFAOYSA-N 3-(2,3,3a,4-tetrahydropyrazolo[3,4-b]pyrazin-1-yl)-1H-imidazol-2-one Chemical compound O=C(NC=C1)N1N1NCC2NC=CN=C12 DLXWQDKMPJRDRU-UHFFFAOYSA-N 0.000 title 1
- BEJNFSHENVLWBC-UHFFFAOYSA-N 3-(2,3,3a,4-tetrahydropyrazolo[4,3-b]pyridin-1-yl)-1H-imidazol-2-one Chemical class O=C(NC=C1)N1N1NCC2NC=CC=C12 BEJNFSHENVLWBC-UHFFFAOYSA-N 0.000 title 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La solicitud se refiere a un compuesto de la fórmula (I): (ver Fórmula) (I), o a una sal, hidrato, solvato, profármaco, estereoisómero o tautómero farmacéuticamente aceptables, que modulan la actividad del receptor de GLP-1, a una composición farmacéutica que comprende un compuesto de la fórmula (I), y a un método para el tratamiento o la prevención de una enfermedad en la que desempeñe una función el receptor de GLP-1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020102955 | 2020-07-20 | ||
CN2021070120 | 2021-01-04 | ||
PCT/CN2021/107216 WO2022017338A1 (en) | 2020-07-20 | 2021-07-20 | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000943A true MX2023000943A (es) | 2023-02-22 |
Family
ID=77167918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000943A MX2023000943A (es) | 2020-07-20 | 2021-07-20 | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (2) | US20230051320A1 (es) |
EP (1) | EP4182020A1 (es) |
JP (1) | JP2023534983A (es) |
KR (1) | KR20230048056A (es) |
CN (1) | CN116390926A (es) |
AU (1) | AU2021311567A1 (es) |
BR (1) | BR112023000932A2 (es) |
CA (1) | CA3186217A1 (es) |
CL (1) | CL2023000196A1 (es) |
CO (1) | CO2023001407A2 (es) |
IL (1) | IL299704A (es) |
MX (1) | MX2023000943A (es) |
PE (1) | PE20230854A1 (es) |
WO (1) | WO2022017338A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023016546A1 (en) * | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
WO2019166951A1 (en) * | 2018-02-28 | 2019-09-06 | Novartis Ag | Indole-2-carbonyl compounds and their use for the treatment of hepatitis b |
-
2021
- 2021-07-20 PE PE2023000103A patent/PE20230854A1/es unknown
- 2021-07-20 BR BR112023000932A patent/BR112023000932A2/pt unknown
- 2021-07-20 MX MX2023000943A patent/MX2023000943A/es unknown
- 2021-07-20 AU AU2021311567A patent/AU2021311567A1/en active Pending
- 2021-07-20 EP EP21749074.7A patent/EP4182020A1/en active Pending
- 2021-07-20 KR KR1020237005845A patent/KR20230048056A/ko unknown
- 2021-07-20 CN CN202180063652.8A patent/CN116390926A/zh active Pending
- 2021-07-20 US US17/380,084 patent/US20230051320A1/en active Pending
- 2021-07-20 IL IL299704A patent/IL299704A/en unknown
- 2021-07-20 CA CA3186217A patent/CA3186217A1/en active Pending
- 2021-07-20 WO PCT/CN2021/107216 patent/WO2022017338A1/en active Application Filing
- 2021-07-20 JP JP2023504008A patent/JP2023534983A/ja active Pending
- 2021-11-02 US US17/516,932 patent/US11584751B1/en active Active
-
2023
- 2023-01-19 CL CL2023000196A patent/CL2023000196A1/es unknown
- 2023-02-09 CO CONC2023/0001407A patent/CO2023001407A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230048056A (ko) | 2023-04-10 |
CA3186217A1 (en) | 2022-01-27 |
IL299704A (en) | 2023-03-01 |
US20230051320A1 (en) | 2023-02-16 |
PE20230854A1 (es) | 2023-05-29 |
CL2023000196A1 (es) | 2023-09-15 |
BR112023000932A2 (pt) | 2023-10-03 |
JP2023534983A (ja) | 2023-08-15 |
US11584751B1 (en) | 2023-02-21 |
WO2022017338A1 (en) | 2022-01-27 |
EP4182020A1 (en) | 2023-05-24 |
CN116390926A (zh) | 2023-07-04 |
CO2023001407A2 (es) | 2023-02-16 |
AU2021311567A1 (en) | 2023-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
JOP20220101A1 (ar) | مثبطات صغيرة الجزئ لطافر G12C لبروتين ساركوما جرذان Kirsten (KRAS) | |
MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
MX2023007192A (es) | Inhibidores de prmt5. | |
PH12018501390A1 (en) | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof | |
MX2023000943A (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos. | |
PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
MX2022008626A (es) | Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea. | |
MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
MX2011008910A (es) | Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson. | |
SA520411787B1 (ar) | مشتقات بنزيميدازول واستخداماتها | |
MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
MX2022013054A (es) | Derivados de imidazolidinona y uso medico de los mismos. | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
PL1791537T3 (pl) | Pochodne 3-arylotioindolo-2-karboksamidów i ich analogi jako inhibitory kinazy kazeinowej I | |
MX2021012105A (es) | Compuestos de pirrol. | |
JOP20220227A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
MX2022004197A (es) | Inhibidores del factor d del complemento para administracion oral. | |
MX2023001671A (es) | Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis. | |
CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
CA3155875A1 (en) | BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE | |
MX2022005199A (es) | Inhibidores de ssao y uso de los mismos. |